SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Follow-up) — Pierre Le Moyne d'Iberville — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPierre Le Moyne d'Iberville
Date of birth1661-07-16
IdentifiersMRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260
Document date1705-07-28
AuthorMarguerite Delacroix-Boateng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Pre-travel visit for a naval deployment to French Guiana and the French Antilles. [S]

History of Present Illness

Mr. Le Moyne d'Iberville, now 44, returns for his pre-travel vaccines. The squadron is expected to sail early next year for the French Antilles and French Guiana, with weeks ashore near Cayenne and Kourou and possible river work inland, and he expects to be away for many months. He has had no fever since his malaria treatment four months ago. The PCR drawn at his last malaria review was negative. The forearm abscess healed within ten days; the culture grew methicillin-susceptible Staphylococcus aureus, and he needed no antibiotic. His screening tests from the preventive visit were negative for HIV and hepatitis C, and the hepatitis B panel shows he is not immune and has never been infected. He has no egg or gelatin allergy, no thymus disease, no immune-suppressing illness or treatment, and has never had yellow fever vaccine. [S]

ElementDetail
DestinationFrench Antilles and French Guiana, many months, partly inland
DepartureEarly next year
MalariaNo fever in four months
ScreeningHIV and hepatitis C negative; not immune to hepatitis B
Vaccine screeningNo contraindication to yellow fever vaccine

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or weight loss
IntegumentaryNegativeForearm healed; no other skin infections
Allergic and immunologicNegativeNo vaccine, egg or gelatin allergy; no immune disorder

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total)Oral route1705-03-03 to 1705-03-05completedS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days30 mg base once daily for 14 daysOral route1705-03-03 to 1705-03-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1705-07-28Body height175cmS
1705-07-28Body weight69.4kgS
1705-07-28Body mass index (BMI) [Ratio]22.7kg/m2S
1705-07-28Systolic blood pressure124mm[Hg]S
1705-07-28Diastolic blood pressure78mm[Hg]S
1705-07-28Heart rate66/minS
1705-07-28Respiratory rate14/minS
1705-07-28Body temperature36.7CelS
1705-07-28Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 1705-07-28; see the Vital Signs section. [S]

SystemFinding
GeneralWell; temperature 36.7 C, blood pressure 124/78, pulse 66, weight 69.4 kg
Right forearmSmall healed scar; no redness

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requestedresolvedconfirmed R50.9S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation.
Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PDresolvedconfirmed B51.9S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic.
Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccinesactiveconfirmed Z71.84S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705.
Small cutaneous abscess of the right forearm, about 2 cm, from a wooden splinter in the dockyard, without fever, spreading cellulitis or systemic signs; drained, without antibiotics; methicillin-susceptible Staphylococcus aureus on culture; resolvedresolvedconfirmed L02.413S — Synthetic acute problem; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationYellow fever vaccine: indication, entry requirement, contraindications and precautionsOnce, before travelCompleted todayRequired for entry to French Guiana; no contraindication; age under 60; dose given and certificate issued
ExaminationHepatitis A, hepatitis B and typhoid vaccinesBefore travelCompleted todayHepatitis A dose 1, typhoid Vi and HepB-CpG dose 1 given
ExaminationRabies pre-exposure vaccinationDiscuss before travelNot indicatedDogs with rabies are uncommon in French Guiana; rabies is present in bats. His duties are shipboard and coastal; after discussion he chose not to have it and knows to seek post-exposure care after any bite or scratch
Medication safetyMalaria chemoprophylaxis choiceBefore travelDueTo be prescribed at the pre-departure visit
Self-managementRelapse surveillance and the fever action planEvery visitCompleted todayNo fever in four months

Goal progress:

Immunizations given today: Yellow fever vaccine, live, single dose; certificate (ICVP) issued, valid from ten days after vaccination; Hepatitis A vaccine, adult, dose 1 of 2; Typhoid Vi polysaccharide vaccine; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]

Guideline basis: CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026); French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006)

Follow-up: Pre-departure review in about eleven weeks. Next scheduled visit 1705-10-13: pre-departure review: no relapse, malaria chemoprophylaxis, vector, food and water precautions, standby treatment, and the plan on return. [S]